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ebola virus (eBoV) is an enveloped, single-stranded RnA virus that can cause ebola virus disease 
(eVD). it is thought that eVD survivors are protected against subsequent infection with eBoV and that 
neutralising antibodies to the viral surface glycoprotein (Gp) are potential correlates of protection. 
Serological studies are vital to assess neutralising antibodies targeted to eBoV Gp; however, 
handling of EBOV is limited to containment level 4 laboratories. Pseudotyped viruses can be used as 
alternatives to live viruses, which require high levels of bio‑containment, in serological and viral entry 
assays. However, neutralisation capacity can differ among pseudotyped virus platforms. We evaluated 
the suitability of EBOV GP pseudotyped human immunodeficiency virus type 1 (HIV‑1) and vesicular 
stomatitis virus (VSV) to measure the neutralising ability of plasma from EVD survivors, when 
compared to results from a live EBOV neutralisation assay. The sensitivity, specificity and correlation 
with live EBOV neutralisation were greater for the VSV‑based pseudotyped virus system, which is 
particularly important when evaluating EBOV vaccine responses and immuno‑therapeutics. Therefore, 
the eBoV Gp pseudotyped VSV neutralisation assay reported here could be used to provide a better 
understanding of the putative correlates of protection against eBoV.
Ebola virus (EBOV), a member of the family Filoviridae, is an enveloped, single-stranded RNA virus that can 
cause Ebola virus disease (EVD), a highly lethal illness with up to 90%  mortality1. Since its discovery in 1976, 
EBOV has caused sporadic outbreaks across Central Africa and was responsible for the 2013–2016 EVD epidemic 
in West  Africa2, which was the largest EBOV outbreak on record and resulted in more than 28,600 cases and over 
11,300  deaths3. This outbreak constituted a public health emergency of international concern and highlighted 
the urgent need for vaccines and therapeutics against EBOV.
The EBOV RNA genome is approximately 19 kb in length and encodes seven main proteins. The envelope gly-
coprotein (GP) of EBOV forms homotrimeric spikes that project from the surface of the viral  particles4. Surface 
GP is critical for host cell attachment and  fusion5,6 and is a target for neutralising  antibodies7. Survivors of EVD 
are thought to protected against subsequent EBOV infection and neutralising antibodies to the viral surface GP 
are possible correlates of  protection8,9. Serological assays, such as the plaque reduction neutralisation test (PRNT), 
are central to evaluate neutralising antibodies against EBOV GP. However, because of its severe pathogenicity, 
potential transmission from person-to-person and lack of approved vaccines or antiviral treatments, handling of 
EBOV is restricted to containment level (CL) 4 laboratories. High containment facilities are expensive and are not 
readily available, especially in countries and organisations with limited resources. Furthermore, the assay format 
open
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and time required for plaque development, which can take approximately nine days, makes it time-consuming 
and restricts high-throughput sample processing. Development of novel serological assays that utilise geneti-
cally modified recombinant or chimeric viruses with attenuated pathogenicity have enabled more widespread 
investigation of neutralising antibodies against highly pathogenic viruses including  EBOV10,11.
Pseudotyped viruses are replication-defective chimeric virions that comprise the structural and enzymatic 
core of one virus, bearing the envelope protein or glycoprotein of another, and encode a quantifiable reporter 
gene. Retroviruses, including lentiviruses and gammaretroviruses such as human immunodeficiency virus (HIV) 
and murine leukaemia virus (MLV), respectively, and rhabdoviruses, such as vesicular stomatitis virus (VSV), 
have been used extensively as cores for pseudotyped  viruses12,13, including for  EBOV14,15. A number of EBOV 
GP pseudotyped virus neutralisation assays have been developed to investigate immune responses to EBOV 
infection and  vaccination16–18, as well as for evaluation of monoclonal antibody (mAb)  therapies19–21.
There are many factors that need to be considered when developing and optimising pseudotyped virus neu-
tralisation assays, to assess experimental parameters that can affect assay performance and to ensure accuracy 
and reproducibility. These include, choice of core virus and reporter gene, determination of target cell line and 
amount of pseudotyped virus input, as well as correlation with live virus  neutralisation22. The aim of this study 
was to assess the suitability of EBOV GP pseudotyped HIV-1 and VSV systems to measure neutralisation by 
EVD survivor plasma, in comparison with results from a live EBOV neutralisation assay.
Results
Cell tropism of EBOV GP pseudotyped viruses.  Pseudotyped HIV-1 and VSV bearing the envelope 
GP from EBOV (Mayinga) were generated and quantified by measuring luminescence in a range of target cell 
lines, in order to determine the optimum cell line to use in neutralisation assays. Cells only controls were used to 
determine background levels of luminescence (Supplementary Fig. S1). Reporter activity was detected in all cell 
lines infected with EBOV GP pseudotyped HIV-1 and VSV, demonstrating the broad tissue range conferred by 
EBOV GP, although differences in luminescence were observed (Fig. 1a,b). For EBOV GP pseudotyped HIV-1, 
highest  TCID50/ml values were observed in 293T/17 cells, followed by Huh-7 cells (Fig. 1c). Titres generated by 
infection of 293T/17 cells were approximately 3, 33 and 73 times greater than those produced by infection of 
Huh-7, HeLa and Vero E6 cells, respectively. For EBOV GP pseudotyped VSV, highest titres were obtained in 
Figure 1.  Titration of EBOV (Mayinga) GP pseudotyped (a) HIV-1 and (b) VSV using different cell lines. 
Relative luminescence units per well (RLU/well) were measured. Error bars are one standard error above and 
below the mean, n = 4. EBOV GP pseudotyped (c) HIV-1 and (d) VSV titres expressed as 50% tissue culture 
infectious dose per ml  (TCID50/ml), n = 1.
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Vero E6 cells. The  TCID50/ml values generated by infection of Vero E6 cells were approximately 1.5, 22 and 30 
times greater than those produced by infection of 293T/17, Huh-7 and HeLa cells, respectively (Fig. 1d). Based 
on these results, the 293T/17 and Vero E6 target cell lines were selected for use in all subsequent neutralisation 
assays using EBOV GP pseudotyped HIV-1 and VSV, respectively.
Neutralisation of EBOV GP pseudotyped viruses by anti‑EBOV GP mAb.  During the initial stages 
of assay development, it is important to evaluate neutralisation of pseudotyped viruses using well characterised 
antibodies in order to demonstrate the validity and accuracy of the assay. The EBOV GP pseudotyped viruses 
were assessed for neutralisation by the human anti-EBOV GP mAb, KZ52. KZ52 is an antibody isolated from a 
human survivor of the 1995 outbreak in Kikwit that neutralises EBOV in vitro and recognises a conformational 
epitope at the base of the  GP23–25. Human anti-EBOV GP mAb, KZ52 was unable to neutralise the EBOV GP 
pseudotyped HIV-1 (Fig. 2a) within the range tested, however it was able to neutralise the EBOV GP pseudo-
typed VSV (Fig. 2b), suggesting that VSV-based pseudotyped viruses are more sensitive to neutralisation then 
lentiviral-based, possibly the density of EBOV GP on the pseudotyped HIV-1 may differ from that on the pseu-
dotyped VSV or live EBOV.
Assessment of EBOV GP pseudotyped virus input for neutralisation.  To determine the optimal 
pseudotyped virus input to use in the HIV- and VSV-based assays, neutralisation of different amounts of the 
EBOV GP pseudotyped viruses by plasma from a Guinean EVD survivor donor or human anti-EBOV GP mAb 
KZ52 was assessed. KZ52 was selected as it is commercially available and there is accompanying information 
regarding its neutralisation activity against EBOV GP pseudotyped VSV expressing luciferase. However, as the 
EBOV GP pseudotyped HIV-1 was not neutralised by KZ52 (Fig. 2a) in the range tested, plasma from an EVD 
survivor was used to assess the effect of pseudotyped HIV-1 input on neutralisation instead. Survivor plasma 
sample CS001 was chosen as it displayed strong neutralising ability against live EBOV neutralisation, with a 
geometric mean titre (GMT) of 1,218. Percentage infectivity was determined relative to infectivity of cells by 
the EBOV GP pseudotyped viruses alone (Fig. 3a,b) and 50% inhibitory concentration  (IC50) of pseudotyped 
virus neutralisation were estimated by model of nonlinear regression dose–response curves (Fig. 3c,d). Plasma 
from EVD survivor CS001 displayed neutralising activity against all amounts of EBOV GP pseudotyped HIV-1 
tested (Fig. 3a). Lower pseudotyped virus input resulted in larger variability and less curve fitting. Therefore, an 
EBOV GP pseudotyped HIV-1 input of at least 8.6 × 104 RLU/well, with a target input of 2.0 × 105 RLU/well, was 
used in subsequent neutralisation assays. KZ52 neutralised all dilutions of EBOV GP pseudotyped VSV tested 
(Fig. 3b) and  IC50 values decreased with decreasing amounts of pseudotyped virus input (Fig. 3d, Supplementary 
Table S1). When using 3.9 × 104 RLU/well of EBOV GP pseudotyped VSV,  IC50 of virus neutralisation (0.07 µg/
ml) was similar to that expected according to the manufacturer’s product data sheet (0.06 µg/ml). Therefore, a 
target input of approximately 3.7 × 104 RLU/well was used in subsequent EBOV GP pseudotyped VSV neutrali-
sation assays.
Neutralisation of EBOV GP pseudotyped viruses by EVD survivor plasma.  In order to compare 
the specificity and sensitivity of EBOV GP pseudotyped HIV-1 and VSV-based assays, we evaluated neutralisa-
tion of the EBOV GP pseudotyped HIV-1 and VSV using plasma samples collected from 30 EVD survivors of 
the 2013–2016 EBOV outbreak and 10 negative control donors from Guinea. The  IC50 of pseudotyped virus neu-
tralisation were estimated by model of nonlinear regression dose–response curves (Supplementary Table S2). 
Neutralisation of EBOV GP pseudotyped HIV-1 and VSV by positive (EVD survivor) and negative (UK donor) 
control plasma was assessed in several independent assays (Supplementary Fig. S2). The background level of 
neutralisation was determined using plasma from a UK negative control donor. For the HIV-1-based assay this 
was calculated as  IC50 6.28 reciprocal dilution. The negative control plasma displayed no neutralising activity 
against EBOV GP pseudotyped VSV, and therefore the background level of neutralisation was assigned the low-
Figure 2.  Neutralisation of EBOV (Mayinga) GP pseudotyped (a) HIV-1, n = 2, and (b) VSV, n = 4, by human 
anti-EBOV GP mAb, KZ52. Percentage infectivity was calculated relative to pseudotyped virus only controls. 
Data are shown for mean with log (inhibitor) vs. normalised response curves. Error bars are 1 standard error 
above and below the mean. Dotted lines represent 50% infectivity.
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est dilution of sample tested in the assay (1/20). In the HIV-1-based assay, dose–response curves were unable to 
be fitted for three of the 30 EVD survivor samples and six of the samples were deemed below the background 
level of neutralisation. In contrast, a dose–response curve was unable to be fitted for only one of the EVD sur-
vivor samples tested in the VSV-based neutralisation assay. In the HIV-1-based assay, three of the 10 negative 
plasma samples tested were above the background level of neutralisation, whereas only one of the negative 
samples tested was above the background level of neutralisation in the VSV-based assay. Although some differ-
ences in the discriminatory power of positive and negative samples between the assays were observed, a statisti-
cally significant difference in neutralisation titres was detected between the EVD survivors and negative plasma 
samples in the HIV-1-based assay (Mann–Whitney, p = 0.0054) (Fig. 4a) and in the VSV-based assay (Mann–
Whitney, p < 0.0001) (Fig. 4b, Supplementary Table S3). Remarkably, this difference was more significant and 
the separation of the positive and negative plasma was better in the VSV-based assay (Fig. 4b). The sum of these 
results clearly show that the VSV-based EBOV GP neutralisation assay displayed better reliability, specificity and 
sensitivity compared to the HIV-1-based assay.
correlation with live eBoV neutralisation. The neutralising capacity of the individual plasma samples 
against authentic EBOV was assessed by a live virus neutralisation assay (Supplementary Table S3, Supplemen-
tary Fig. S3). When  IC50 values of EBOV GP pseudotyped HIV-1 neutralisation of the 30 EVD survivor and 10 
negative plasma samples were compared with GMT values for the live EBOV neutralisation assay, a positive 
correlation (rs = 0.54) was determined using the nonparametric Spearman correlation coefficient (Fig. 5a) and 
this was statistically significant (p = 0.0004). Remarkably, a stronger statistically significant (p < 0.0001) positive 
correlation (rs = 0.86) was observed when  IC50 values of EBOV GP pseudotyped VSV neutralisation were com-
pared with GMT values for the live EBOV neutralisation assay (Fig. 5b). The correlation coefficients for EBOV 
GP HIV-1 and VSV  IC50 compared with live EBOV GMT without the negative controls were 0.38 (p = 0.0375) 
and 0.69 (p < 0.0001), respectively. Therefore, the VSV-based EBOV GP pseudotyped virus neutralisation assay 
correlated better with live EBOV neutralisation than the HIV-1-based neutralisation assay.
Figure 3.  Effect of EBOV (Mayinga) GP pseudotyped (a) HIV-1 input on neutralisation by EVD survivor 
(CS001) plasma, n = 2, and (b) VSV by anti-EBOV GP mAb, KZ52, n = 4. Percentage infectivity was calculated 
relative to pseudotyped virus only controls. Data are shown for mean with log (inhibitor) vs. normalised 
response curves. Error bars are 1 standard error above and below the mean. Dotted lines represent 50% 
infectivity. The  IC50 of EBOV GP pseudotyped (c) HIV-1 and (d) VSV neutralisation were estimated by model 
of nonlinear regression dose–response curves, n = 1.
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Discussion
Pseudotyped viruses can be used as alternatives to infectious virus in serological assays to measure neutralis-
ing antibodies to viral envelope  glycoproteins11. Pseudotyped virus assays used to profile neutralising antibody 
responses against severe acute respiratory syndrome-associated coronavirus (SARS-CoV)26, influenza (H5N1 and 
H7N9)27–29,  rabies30,31 and chikungunya  virus32, for example, found that results correlated well with those from 
replication-competent or live virus assays. A high degree of correlation has been demonstrated between EBOV 
CL4 PRNT and an EBOV pseudotyped VSV CL2 fluorescence reduction neutralisation test (FRNT)33. However, 
pseudotyped virus assays may not always accurately determine  neutralisation34,35. Live EBOV and EBOV GP 
pseudotyped neutralisation assays have previously been shown to yield variable  results8,36, which could be due 
to differing experimental conditions and viral systems. It is therefore important to optimise pseudotyped virus 
neutralisation assays in context of the particular viral GP being studied in order to obtain reliable specificity and 
sensitivity. The aim of this study was to assess the suitability of EBOV GP pseudotyped HIV-1 and VSV systems 
to measure the neutralising ability of plasma from EVD survivors, when compared to live EBOV neutralisation.
Reporter activity was detected in all cell lines (293T/17, Huh-7, HeLa and Vero E6) infected with EBOV GP 
(Mayinga) pseudotyped HIV-1 and VSV, demonstrating the broad tissue range conferred by EBOV GP, although 
differences in luminescence were observed. This may reflect general defects in viral entry in different cells. A 
relatively lower level of EBOV GP pseudotyped HIV-1 transduction was exhibited by Vero E6 cells, which might 
be due to an intrinsic restriction factor, TRIM5α, which restricts retroviral infection by specifically recognising 
the HIV-1 capsid and promoting its rapid, premature  disassembly37. Highest  TCID50 values were obtained follow-
ing EBOV GP pseudotyped HIV-1 and VSV infection of 293T/17 and Vero E6 cells, respectively. There seemed 
to be large variability of the luminescent measurement for the VSV-based platform, which may be caused by the 
Figure 4.  Neutralisation of EBOV (Mayinga) GP pseudotyped (a) HIV-1 and (b) VSV by EVD survivor and 
negative plasma samples. The  IC50 of pseudotyped virus neutralisation were estimated by model of nonlinear 
regression dose–response curves. Data are shown for individuals and the geometric mean with 95% confidence 
interval (95% CI). Dotted lines represent background level of neutralisation. Background level of pseudotyped 
HIV-1 neutralisation  (IC50 6.28 reciprocal dilution) is equal to UK negative control plasma mean plus two 
standard deviations, n = 7. Background level of pseudotyped VSV neutralisation is equal to the lowest dilution 
of sample tested in the assay (1/20). Statistically significant differences are highlighted (**p < 0.01, ****p < 0.0001; 
Mann–Whitney).
Figure 5.  Correlation of EBOV GP pseudotyped (a) HIV-1 and (b) VSV  (IC50) with live EBOV (GMT) 
neutralisation using the nonparametric Spearman correlation coefficient, n = 40. Dotted lines represent 
background level of neutralisation. Background level of pseudotyped HIV-1 neutralisation  (IC50 6.28 reciprocal 
dilution) is equal to UK negative control plasma mean plus two standard deviations, n = 7. Background 
level of pseudotyped VSV neutralisation is equal to the lowest dilution of sample tested in the assay (1/20). 
Seropositivity in the live EBOV neutralisation assay is defined by a GMT > 8.
6Vol:.(1234567890)
Scientific RepoRtS |        (2020) 10:14289  | https://doi.org/10.1038/s41598-020-71225-1
www.nature.com/scientificreports/
sensitive nature of the luciferase signal detection. This highlights the importance of titrating each pseudotyped 
virus batch before use in neutralisation assays, and the inclusion of multiple replicates.
The EBOV GP pseudotyped viruses were used to assess the neutralising activity of a human anti-EBOV GP 
mAb, KZ52. KZ52 has been shown previously to neutralise EBOV pseudotyped  viruses17,19,38. However, within 
the range tested here, KZ52 did not display neutralisation against EBOV GP pseudotyped HIV-1, suggesting 
that the EBOV GP on the pseudotyped HIV-1 might be at higher levels, thereby reducing assay sensitivity, and 
neutralisation may be observed using a higher concentration of KZ52. In contrast, KZ52 was able to neutralise 
the EBOV GP pseudotyped VSV.
To assess the effects of differing amounts of pseudotyped virus input on neutralisation, plasma from an EVD 
survivor of the 2013–2016 EBOV outbreak and KZ52 were screened against different amounts of the EBOV GP 
pseudotyped HIV-1 and VSV, respectively. Decreasing quantities of pseudotyped HIV-1 led to more variable and 
unreliable results, and the KZ52  IC50 of pseudotyped virus neutralisation decreased with decreasing amounts 
of EBOV GP pseudotyped VSV input. The variability in neutralisation observed between different amounts of 
pseudotyped virus input highlights the importance of including standards or reference material with a known 
activity or potency when comparing neutralising activity, allowing calibration of  results39.
Both pseudotyped virus systems were able to measure neutralising antibodies in plasma from EVD convales-
cent patients, and results correlated positively with a live EBOV neutralisation assay. However, the discrimina-
tory power of the HIV-1-based assay with regards to differing antibody titres appeared to be low. Some of the 
samples tested, which showed neutralising activity against live EBOV, did not display neutralisation against the 
pseudotyped virus and vice versa, therefore raising questions on the sensitivity and specificity of the pseudotyped 
HIV-1 assay.
In the current study, human embryonic kidney (293T/17) cells were used for the pseudotyped HIV-1 neu-
tralisation assays, whereas African green monkey kidney (Vero) cells were used in the VSV-based assay and also 
the live EBOV assay. Therefore, this could account for some of the differences in results observed between the 
two assays and for the better performance of the VSV-based assay in relation to live EBOV neutralisation. Also, 
the HIV-1- and VSV-based pseudotyped virus systems assessed in the current study utilise different transfec-
tion methods, which could have implications on the composition of the pseudotyped viruses, density and/or 
glycosylation of the viral envelope protein on the surface, and consequently neutralisation results. This high-
lights the importance of assessing experimental conditions and methodology when developing and optimising 
pseudotyped virus neutralisation assays. A limitation to this study was that the level of EBOV GP incorporation 
per pseudotyped virus type could not be assessed. Also, for the VSV-based pseudotyped virus system, traces of 
VSV-G from the rVSV-ΔG-Luc-VSV-G virus could be recycled into newly pseudotyped  virions40. Therefore, 
the use of anti-VSV-G hybridoma cell culture supernatant could give rise to pseudotyped virions covered by 
anti-VSV-G antibodies, but are still infectious due to Ebola GP. This could potentially induce plasma specific 
reactivity of virions due to bound anti-VSV-G antibodies more than EBOV GP specific reactivity.
There are several differences between EBOV GP pseudotyped and live EBOV neutralisation assays that could 
affect their  results8. Due to their non-replicating nature, such pseudotype systems do not recapitulate all steps in 
the viral life cycle that may potentially be targeted by neutralising  antibodies41. In addition, the round, spherical 
shape of EBOV GP pseudotyped HIV-1 or bullet shape of EBOV GP pseudotyped VSV compared to the fila-
mentous shape of authentic EBOV could affect their susceptibility to neutralisation. Also, the density of GP on 
the surface of the pseudotyped virus may not be the same as that found on live EBOV and may result in the loss 
or masking of quaternary  epitopes11,42. Furthermore, GP maturation and assembly in live EBOV could be differ-
ent in the generation of an EBOV pseudotyped virus and may result in different targets and/or conformational 
epitopes when using whole live EBOV as opposed to EBOV GP alone in a pseudotyped virus. The presence of 
shed GP or secreted GP (sGP) in the live EBOV assay compared to absence in the EBOV GP pseudotyped virus 
assays could also have an effect on neutralisation. In the live EBOV assay, shed GP and sGP could reduce neu-
tralisation of circulating virus by cross-reactive antibodies to surface GP. However, in the current study, weaker 
relative neutralisation was observed in the HIV-1 based pseudotyped virus assay. Therefore, it is possible that 
cell debris or free GP generated during EBOV GP pseudotyped HIV-1 production by polyethylenimine (PEI) 
transfection could be interfering with neutralisation. Finally, detection of infected cells via measurement of 
luminescence in the EBOV GP pseudotyped virus neutralisation assay compared to plaque formation in the live 
EBOV neutralisation assay could affect neutralisation readout.
EBOV GP pseudotyped virus neutralisation assays have value for vaccine evaluation and assessment of con-
valescent blood products and mAbs for use as immunotherapeutics. However, pseudotyped virus assays may not 
always accurately determine neutralisation when compared with neutralisation against live virus. In this study, 
both EBOV GP pseudotyped HIV-1 and VSV assays were able to detect neutralisation of plasma from EVD sur-
vivors and correlated positively with live EBOV neutralisation. However, the VSV-based assay performed better 
than the HIV-1-based assay in relation to specificity, sensitivity, and correlation with the live EBOV neutralisation 
assay. This research has highlighted the importance of optimising pseudotyped virus neutralisation assays in 
context of the particular viral GP being studied, especially when evaluating vaccine responses and therapeutics, 
and could provide a better understanding of the correlates of protection against EBOV.
Methods
Plasmids and cells.  The HIV-1 gag-pol plasmid p8.9143, the firefly luciferase reporter construct  pCSFLW44 
and a pCAGGS EBOV (Mayinga) GP (GenBank accession number NC_002549) expression construct were kind 
gifts from Edward Wright[University of Sussex, Brighton, United Kingdom (UK)].
Human embryonic kidney (HEK) 293T clone 17 cells (293T/17; American Type Culture Collection (ATCC), 
Teddington, UK, CRL-11268) were used for all transfections and as a target cell line for titration and pseudotyped 
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HIV-1 neutralisation assays. Vero E6[Vero 76, clone E6, Vero E6 (European Culture of Authenticated Cell Cul-
tures (ECACC), Salisbury, UK, 85020206) and Huh-7 (Arvind Patel, University of Glasgow, UK) cells were used 
as target cell lines. All cell lines were cultured at 5%  CO2 in Dulbecco’s Modified Eagle Medium (DMEM), high 
glucose, with l-glutamine (Gibco, Paisley, UK) supplemented with 10% fetal bovine serum (FBS), heat inactivated 
(Sigma-Aldrich, Gillingham, UK). HeLa cells (ECACC 93021013) were also used as a target cell line and were 
cultured in Minimum Essential Media (MEM) + GlutaMAX (Life Technologies, Paisley, UK) supplemented with 
10% FBS and 1 × MEM Non-Essential Amino Acids (NEAA) solution (Life Technologies).
Human samples and purified human antibody.  Plasma samples from EVD survivors of the 2013–2016 
EBOV outbreak recruited 3 to 14 months post-infection from two regions of Guinea (Guéckédou and Coyah) 
and from negative control blood donors in the UK and Guinea, who were not knowingly exposed to persons 
with EVD and did not attend high risk events such as funerals, were heat inactivated at 56 °C for 30 min. The 
samples were obtained from a pre-existing biobank, for which live EBOV  neutralisation45 data were available 
(Thomas Strecker, Philipps University Marburg, Germany) in link-anonymised format. All experiments involv-
ing live EBOV were performed in a CL4 facility at Philipps University Marburg, Germany. The biobank was 
established by Horizon 2020 EU research initiative ‘EVIDENT’. All experimental protocols used in this study 
were approved by the Guinean National Ethics Committee for Research and Health [Comité National d’Ethique 
pour la Recherche en Santé (CNERS)]. All methods were carried out in accordance with the relevant guidelines 
and regulations under ethical approval No. 33/CNERS/15. Informed consent was obtained from all participants.
Protein A purified human anti-EBOV GP mAb KZ52 (IBT Bioservices Rockville, Maryland (MD), USA) was 
also tested in the EBOV GP pseudotyped virus neutralisation assays.
production of pseudotyped viruses. The generation of HIV-1 pseudotyped viruses was performed as 
detailed  previously44,46,47. Twenty-four hours prior to transfection, approximately 8 × 105 293T/17 cells were 
seeded into sterile, 6-well cell culture plates (Corning, Ewloe, UK) and incubated at 37 °C, 5%  CO2 and 95% 
humidity until 60–80% confluence. The HIV gag-pol plasmid, p8.91, and the firefly luciferase reporter con-
struct, pCSFLW, were transfected simultaneously with the EBOV (Mayinga) GP expression vector at a ratio of 
0.6:0.9:0.6 µg (core:reporter:envelope) using 10 µl of 1 µg/ml polyethylenimine (PEI) (Sigma-Aldrich) per 1 µg 
DNA in Opti-MEM medium (Gibco). Following overnight transfection, the cells were incubated with fresh 
medium and incubated at 37 °C, 5%  CO2. Pseudotyped virus supernatants were harvested at 48 and 72 h post-
transfection, passed through a 0.45 µm pore filter (Millex, Millipore, Watford, UK) and stored at − 80 °C.
EBOV GP pseudotyped VSVs were prepared using recombinant VSV, in which the VSV-G gene had been 
deleted (rVSV-ΔG) and replaced with a luciferase reporter gene (rVSV-ΔG-Luc) by a method similar to that 
described  previously48. Twenty-four hours prior to transfection, approximately 2.4 × 106 293T/17 cells were 
seeded into sterile, 100 mm cell culture dishes (Corning) and incubated at 37 °C, 5%  CO2 and 95% humidity 
until 60–80% confluence. The cells were transfected with the EBOV GP expression vectors using TransIT-LT1 
Transfection Reagent (Mirus Bio, Madison, Wisconsin (WI), USA) as per the manufacturer’s instructions. Fol-
lowing overnight transfection, the medium was removed and the cells were infected with rVSV-ΔG-Luc that was 
pseudotyped with the VSV glycoprotein (rVSV-ΔG-Luc-VSV-G) (Masayuki Saijo, National Institute of Infectious 
Diseases, Tokyo, Japan) at a multiplicity of infection (MOI) of 5 in Opti-MEM medium and incubated at 37 °C, 
5%  CO2. After 2 h, the inoculum was removed, cells were washed twice with Dulbecco’s phosphate buffered 
saline (DPBS) (Gibco) and fresh medium was added. Pseudotyped virus supernatants were harvested at 18–24 h 
post-infection, clarified twice by centrifugation at 200xg for 5 min at 10 °C and stored at − 80 °C. Prior to use, 
the pseudotyped viruses were incubated with anti-VSV-G hybridoma cell culture supernatant (Masayuki Saijo, 
National Institute of Infectious Diseases, Tokyo, Japan) at a 1:125 dilution for 1 h at 37 °C to reduce background 
infection mediated by residual virus possessing VSV-G, which can be carried over during  preparation48.
All experiments involving pseudotyped viruses were performed in a CL2 facility at Public Health England 
(PHE), Porton Down, UK.
pseudotyped virus titration and neutralisation assays. Titration and neutralisation assays were per-
formed in 96-well solid white flat bottom polystyrene TC-treated microplates (Corning) and were based upon 
previously described  protocols44,46,48.
For pseudotyped HIV-1 titration assays, five-fold serial dilutions of pseudotyped virus at a starting dilution 
of 1:5 were prepared in quadruplicate in Opti-MEM medium at a final volume of 100 µl/well. 100 µl of approxi-
mately 2 × 104 293T/17, Huh-7 or Vero E6 cells, or 1 × 104 HeLa cells were then added to each well and incubated 
at 37 °C, 5%  CO2 for 48 h. The medium was removed and 50 µl of a 50:50 mix of Bright-Glo luciferase assay 
reagent (Promega, Southampton, UK):fresh medium was added to each well and incubated for at least 2 min at 
room temperature to allow complete cell lysis. Luminescence was measured using a Glomax-Multi + detection 
system luminometer (Promega) and relative luminescence units per ml (RLU/ml) were determined. The negative 
cut-off was set at 2.5 times the average RLUs of the cells only control wells. 50% tissue culture infectious dose 
 (TCID50)/ml values were determined using the Reed-Muench  method49.
For the pseudotyped HIV-1 neutralisation assay, two or threefold serial dilutions of plasma samples at a 
starting dilution of 1:5 or 1:10, respectively, were prepared in duplicate in Opti-MEM medium at a final volume 
of 50 µl/well and incubated with 50 µl of a standardised RLU per well of pseudotyped virus (as calculated from 
the titration assay), prepared in Opti-MEM medium, for 1 h at 37 °C. 100 µl of approximately 2 × 105 293T/17 
cells were then added to each well and incubated for 48 h at 37 °C, 5%  CO2, prior to taking a chemiluminescent 
readout as described above. Infectivity was calculated using the formula: Percentage (%) infectivity = [(RLU with 
sample)/(RLU without sample)] × 100.
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For pseudotyped VSV titration assays, 24 h prior, approximately 2.5 × 104 293T/17 or 1 × 104 Huh-7, HeLa 
cells or Vero E6 cells were seeded in 96-well microplates and incubated at 37 °C, 5%  CO2 and 95% humidity. The 
medium was removed and two-fold serial dilutions of pseudotyped virus in Opti-MEM medium, starting with 
neat pseudotyped virus were added to each well in quadruplicate at a final volume of 100 µl/well. After 24 h, a 
chemiluminescent readout was taken and  TCID50/ml values were determined as described above.
Twenty-four hours prior to pseudotyped VSV neutralisation, approximately 1 × 104 Vero E6 cells were seeded 
and incubated as for titration above. Twofold serial dilutions of plasma samples at a starting dilution of 1:10 
were prepared in duplicate in Opti-MEM medium at a final volume of 120 µl/well in 96-well microplates, and 
incubated with 120 µl of a standardised RLU per well of pseudotyped virus (as calculated from the titration 
assay), prepared in Opti-MEM medium, for 1 h at 37 °C. The medium was removed from the cells, 50 µl of the 
plasma-pseudotyped virus mixtures were added to each well in quadruplicate at incubated at 37 °C, 5%  CO2. 
After 1 h, 50 µl of fresh medium was added to each well. Luminescence was measured after 24 h and infectivity 
was calculated as described above.
Statistical analysis. Pseudotyped virus neutralisation assay raw data were normalised as percentage (%) 
infection relative to mean values for pseudotyped virus only controls (equivalent to 100% infection), then  IC50 
of pseudotyped virus neutralisation were estimated by model of nonlinear regression fit with settings for log 
(inhibitor) vs. normalised response curves using GraphPad Prism v5 (San Diego, California (CA), USA).
Statistical comparison between two unpaired groups was performed using the Mann–Whitney test (Graph-
Pad Prism v5). Correlation between two variables was quantified using Spearman nonparametric correlation 
(GraphPad Prism v5).
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